Monoclonal antibodies therapy is considered a promising method for cancer treatment, according to selectivity and efficacy . But cancer cell genetic polymorphism and high mutational rate reduced the expected therapeutic level. It is not forgotten, cancer cells have their own immune cells such as immature dendritic cells and tumor associated macrophages which are used for metastasis and progression. Besides that, cancer has a role of regulatory T cells activation which in result, will suppress the patient immune system, as a consequence , less phagocytosis of malignant cells. The suggested modification will solve that problem to a big extent besides elevation the high affinity of the monoclonal antibody. Glycosylation of the monoclonal antibody Fc portion by solamargine is prospective. It is well known that tumor cells need high glycoside supply for their high metabolic and replication activity. Solamargine as a glycoalkaloid glycoside, has an advantage of malignant cell high uptake, so it will facilitate MAB endocytosis. Also, it facilitates the intrinsic and the extrinsic pathway of apoptosis. Here in, the role of gallium comes when retained for a long time inside cancer cell after complexion with its DNA. The malignant cell genes constitute the factory of the multiple resistance cancers of cancer by production different cancerous proteins and antigens. Arresting the cancer cell mutations by gallium-DNA complexes will make it easier for solamargine and patient different immune components for apoptosis and phagocytosis respectively. That modification can be applied for all monoclonal antibodies because it occurs in the constant Fc portion with preservation of the variable Fab portion of each MAB.

To be added